아이오바이오 Stock: price and insider trades · South Korea

아이오바이오 is a Health Care company. Its directors and officers file their transactions with DART (FSS). From 10 November 2025 to 10 November 2026, the disclosure feed for 아이오바이오 logged 1 filing by 1 insider.

No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.

For context, the typical company on the same exchange (median of 2,648 companies) published 7 filings over the same period, against 1 filing here. Since 2022, the database holds no purchases and 4 sales by insiders of the company.

There has been no open-market purchase by an insider of 아이오바이오 for at least a year.

For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.